Detection of serum anti-p53 antibodies from patients with ovarian cancer in China: correlation to clinical parameters.
BACKGROUND
Ovarian cancer has been one of the most common malignant tumor among women in China. The aims of this research were to increase the detection efficiency of anti-p53 antibodies in the sera from patients with ovarian cancer and to assist the diagnosis for patients with ovarian cancer.


METHODS
The hybrid phage displaying the immunodominant epitope SQAMDDLMLS in p53 N-terminal region was constructed and the fusion protein was prepared and purified. Ninety-two nonselected Chinese women with ovarian cancer were involved in this study. Tumor p53 overexpression was assessed by immunohistochemical analysis of tissue sections. Serum antibodies to p53 were also detected by enzyme-linked immunosorbent assay (ELISA) using recombinant human wild-type p53 protein and the hybrid phage as the coating antigen respectively. Furthermore, the correlations between the anti-p53 antibodies and clinicopathological parameters were analyzed.


RESULTS
The positive rate of anti-p53 antibodies in the patients with ovarian cancer was increased (39.1%, 36/92) through the combination of the two ELISA methods compared with each method. The anti-p53 antibodies were not associated with the clinicopathologic parameters, while there was a significant correlation between the presence of p53 Abs and tissue overexpression of p53 in ovarian cancer.


CONCLUSIONS
These preliminary results demonstrate that the combination of the two ELISA methods increased the positive rate of anti-p53 antibodies in patients with ovarian cancer and provided a useful marker to complement routine clinical diagnosis for patients with ovarian cancer.
Qiu
Tian
T
Institute of Genetics and Cytology, School of Life Sciences, Northeast Normal University, Changchun, Jilin Province, P.R. China.
Yang
Qiong
Q
Li
Xing-Rong
XR
Yang
Hua
H
Qiu
Lin-Lin
LL
Wang
Li
L
D000328:Adult; D000368:Aged; D000906:Antibodies / Q000097:blood*; D002681:China; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000276:immunology* / Q000473:pathology; D019151:Peptide Library; D016159:Tumor Suppressor Protein p53 / Q000276:immunology* / Q000378:metabolism
D000906:Antibodies; D019151:Peptide Library; D016159:Tumor Suppressor Protein p53